Kevin Feeley Sells 274 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 274 shares of GeneDx stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $66.60, for a total value of $18,248.40. Following the completion of the sale, the chief financial officer now owns 44,951 shares of the company’s stock, valued at $2,993,736.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Monday, September 9th, Kevin Feeley sold 895 shares of GeneDx stock. The stock was sold at an average price of $33.33, for a total value of $29,830.35.
• On Tuesday, September 3rd, Kevin Feeley sold 262 shares of GeneDx stock. The stock was sold at an average price of $31.71, for a total value of $8,308.02.

GeneDx Stock Down 4.8 %

NASDAQ WGS opened at $77.74 on Friday. GeneDx Holdings Corp. has a twelve month low of $1.16 and a twelve month high of $89.11. The stock has a market cap of $2.09 billion, a PE ratio of -25.00 and a beta of 2.32. The firm has a 50-day simple moving average of $47.44 and a 200 day simple moving average of $33.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.22 and a current ratio of 2.40.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.25. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The firm had revenue of $76.90 million for the quarter, compared to analyst estimates of $64.98 million. During the same period in the previous year, the business earned ($0.82) earnings per share. The company’s revenue for the quarter was up 44.3% compared to the same quarter last year. On average, research analysts forecast that GeneDx Holdings Corp. will post -0.75 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. TD Cowen lifted their price target on GeneDx from $46.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Wells Fargo & Company raised their target price on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday. Craig Hallum boosted their price target on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday. The Goldman Sachs Group upped their price objective on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday. Finally, BTIG Research lifted their price target on shares of GeneDx from $35.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, GeneDx has an average rating of “Moderate Buy” and an average price target of $59.33.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC bought a new stake in shares of GeneDx during the second quarter worth $34,000. nVerses Capital LLC bought a new position in GeneDx during the second quarter worth about $50,000. CWM LLC acquired a new position in shares of GeneDx during the 3rd quarter worth approximately $89,000. SG Americas Securities LLC acquired a new position in shares of GeneDx in the third quarter valued at $198,000. Finally, Palumbo Wealth Management LLC bought a new position in GeneDx in the 3rd quarter valued at about $287,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.